SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 101 filers reported holding SYNDAX PHARMACEUTICALS INC in Q3 2020. The put-call ratio across all filers is 1.24 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,353,901 | -28.5% | 506,467 | +3.1% | 0.00% | -33.3% |
| Q2 2023 | $10,283,139 | +3.6% | 491,311 | +4.5% | 0.00% | 0.0% |
| Q1 2023 | $9,929,906 | -13.1% | 470,166 | +4.8% | 0.00% | -25.0% |
| Q4 2022 | $11,420,458 | +23.4% | 448,741 | +16.5% | 0.00% | +33.3% |
| Q3 2022 | $9,255,000 | +34.8% | 385,121 | +7.9% | 0.00% | +50.0% |
| Q2 2022 | $6,867,000 | +15.8% | 356,905 | +4.6% | 0.00% | 0.0% |
| Q1 2022 | $5,932,000 | -11.4% | 341,304 | +11.5% | 0.00% | 0.0% |
| Q4 2021 | $6,699,000 | +15.9% | 305,996 | +1.1% | 0.00% | 0.0% |
| Q3 2021 | $5,782,000 | +24.9% | 302,527 | +12.2% | 0.00% | 0.0% |
| Q2 2021 | $4,630,000 | -10.3% | 269,631 | +16.8% | 0.00% | 0.0% |
| Q1 2021 | $5,164,000 | +19.4% | 230,933 | +18.8% | 0.00% | 0.0% |
| Q4 2020 | $4,325,000 | +59.6% | 194,468 | +5.9% | 0.00% | +100.0% |
| Q3 2020 | $2,710,000 | +175.1% | 183,568 | +176.4% | 0.00% | – |
| Q2 2020 | $985,000 | +60.9% | 66,419 | +19.1% | 0.00% | – |
| Q1 2020 | $612,000 | +38.8% | 55,758 | +11.2% | 0.00% | – |
| Q4 2019 | $441,000 | +17.6% | 50,164 | 0.0% | 0.00% | – |
| Q3 2019 | $375,000 | -19.9% | 50,164 | 0.0% | 0.00% | – |
| Q2 2019 | $468,000 | +138.8% | 50,164 | +34.8% | 0.00% | – |
| Q1 2019 | $196,000 | +51.9% | 37,217 | +28.9% | 0.00% | – |
| Q4 2018 | $129,000 | -34.2% | 28,882 | +19.4% | 0.00% | – |
| Q3 2018 | $196,000 | +14.0% | 24,182 | -0.9% | 0.00% | – |
| Q2 2018 | $172,000 | -50.6% | 24,400 | 0.0% | 0.00% | – |
| Q1 2018 | $348,000 | +62.6% | 24,400 | 0.0% | 0.00% | – |
| Q4 2017 | $214,000 | -25.2% | 24,400 | 0.0% | 0.00% | – |
| Q3 2017 | $286,000 | +101.4% | 24,400 | +141.6% | 0.00% | – |
| Q2 2017 | $142,000 | +2.2% | 10,100 | 0.0% | 0.00% | – |
| Q1 2017 | $139,000 | +90.4% | 10,100 | 0.0% | 0.00% | – |
| Q4 2016 | $73,000 | -52.6% | 10,100 | 0.0% | 0.00% | – |
| Q3 2016 | $154,000 | +54.0% | 10,100 | 0.0% | 0.00% | – |
| Q2 2016 | $100,000 | – | 10,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |